Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD and Food Effect Study of BLU-808 in Healthy Adults
NCT06948032Phase 1Completed
- Sponsor
- Blueprint Medicines
- Start
- Aug 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BLU-808 in chronic urticaria (CU) and Mast cell disorders (8 arms), sponsored by Blueprint Medicines. Primary endpoints: Treatment-emergent Adverse Events at Day 26, Area Under the Plasma Concentration-time Curve From Time 0 to Last Measurable Concentration at Day 14 and 1 more. Started Aug 2024; status: completed.
02
Drugs
BLU-808
03
Conditions
chronic urticaria (CU)Mast cell disorders
Beyond the preview
Go deeper on NCT06948032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06948032.